BioAdaptives, Inc. (BDPT) stock
BDPTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.00−0.00 (-5.56%)
Close on Oct 19, 2026Market cap $478.03KP/E –Yield –
BioAdaptives total assets
Total assets on the balance sheet at the end of each period.
BioAdaptives's total assets was $78.77K at Jun 30, 2026. For fiscal 2025 it was $225.90K, down 13.7% from the year before. Over ten years it grew 6.5% a year on average. The highest annual figure on record is $261.89K in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.90K | -13.7% |
| FY2024 | Dec 31, 2024 | $261.89K | +151.8% |
| FY2023 | Dec 31, 2023 | $104.00K | +178.7% |
| FY2022 | Dec 31, 2022 | $37.31K | -74.9% |
| FY2021 | Dec 31, 2021 | $148.59K | +688.4% |
| FY2020 | Dec 31, 2020 | $18.85K | -22.2% |
| FY2019 | Dec 31, 2019 | $24.21K | -78.0% |
| FY2018 | Dec 31, 2018 | $110.06K | +1430.7% |
| FY2015 | Dec 31, 2015 | $7.19K | -89.8% |
| FY2014 | Dec 31, 2014 | $70.76K | -41.2% |
| FY2013 | Dec 31, 2013 | $120.31K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $78.77K | -71.1% |
| Q1 FY2026 | Mar 31, 2026 | $135.95K | +23.1% |
| Q4 FY2025 | Dec 31, 2025 | $225.90K | -13.7% |
| Q3 FY2025 | Sep 30, 2025 | $124.36K | +168.1% |
| Q2 FY2025 | Jun 30, 2025 | $272.52K | +3019.8% |
| Q1 FY2025 | Mar 31, 2025 | $110.45K | +88.3% |
| Q4 FY2024 | Dec 31, 2024 | $261.89K | +151.8% |
| Q3 FY2024 | Sep 30, 2024 | $46.39K | -85.9% |
| Q2 FY2024 | Jun 30, 2024 | $8.74K | -81.9% |
| Q1 FY2024 | Mar 31, 2024 | $58.67K | +349.9% |
| Q4 FY2023 | Dec 31, 2023 | $104.00K | +178.7% |
| Q3 FY2023 | Sep 30, 2023 | $329.30K | +1011.9% |
| Q2 FY2023 | Jun 30, 2023 | $48.27K | -30.4% |
| Q1 FY2023 | Mar 31, 2023 | $13.04K | -85.0% |
| Q4 FY2022 | Dec 31, 2022 | $37.31K | -74.9% |
| Q3 FY2022 | Sep 30, 2022 | $29.62K | -83.4% |
| Q2 FY2022 | Jun 30, 2022 | $69.38K | -49.0% |
| Q1 FY2022 | Mar 31, 2022 | $87.07K | -28.6% |
| Q4 FY2021 | Dec 31, 2021 | $148.59K | +688.4% |
| Q3 FY2021 | Sep 30, 2021 | $178.70K | +458.2% |
| Q2 FY2021 | Jun 30, 2021 | $135.97K | +509.6% |
| Q1 FY2021 | Mar 31, 2021 | $121.92K | +356.5% |
| Q4 FY2020 | Dec 31, 2020 | $18.85K | -22.2% |
| Q3 FY2020 | Sep 30, 2020 | $32.01K | +122.0% |
| Q2 FY2020 | Jun 30, 2020 | $22.31K | +4.8% |
| Q1 FY2020 | Mar 31, 2020 | $26.71K | -75.7% |
| Q4 FY2019 | Dec 31, 2019 | $24.21K | -84.4% |
| Q3 FY2019 | Sep 30, 2019 | $14.42K | -90.3% |
| Q2 FY2019 | Jun 30, 2019 | $21.29K | -86.2% |
| Q4 FY2018 | Dec 31, 2018 | $110.06K | +1430.7% |
| Q3 FY2016 | Sep 30, 2016 | $155.66K | +1841.1% |
| Q2 FY2016 | Jun 30, 2016 | $149.32K | – |
| Q1 FY2016 | Mar 31, 2016 | $154.70K | – |
| Q4 FY2015 | Dec 31, 2015 | $7.19K | – |
| Q3 FY2015 | Sep 30, 2015 | $8.02K | – |
See a number that looks wrong?